Next Article in Journal
Febrile Neutropenia Rates with Adjuvant Docetaxel and Cyclophosphamide Chemotherapy in Early Breast Cancer: Discrepancy between Published Reports and Community Practice—A Retrospective Analysis
Previous Article in Journal
Management of Aromatase Inhibitor–Induced Arthralgia
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Article

Systemic Therapies in Metastatic Non-Small-Cell Lung Cancer with Emphasis on Targeted Therapies: The Rational Approach

Medical Oncology Department, MUHC Royal Victoria Hospital, 687 Pine Avenue West, Suite A3.04, Montreal, QC H3A 1A1, Canada
Received: 6 January 2010 / Revised: 3 February 2010 / Accepted: 4 March 2010 / Published: 1 April 2010
Historically, first-line treatment of non-small-cell lung cancer (NSCLC) has been based on giving a limited number of cycles of chemotherapy to achieve tumour response or stable disease. Patients are then observed without active therapy until disease progresses, at which point, subsequent lines of therapy are given. In recent years, two new concepts have been introduced to the management of NSCLC: maintenance therapy and therapy with targeted agents. Maintenance therapy—with either a chemotherapeutic or biologic agent—is given immediately after first-line therapy to patients who have achieved tumour response or stable disease. Choice of therapy may include continuation of the agents included in the induction regimen or introduction of different agents (early second-line treatment) with the aim of preventing progression and prolonging progression-free survival. Targeted agents such as bevacizumab and erlotinib target critical molecular signalling pathways and provide several advantages over chemotherapy, including fewer toxicities and the possibility of a longer duration of therapy. This review examines the treatment options in all lines of therapy for metastatic nsclc, focusing particularly on targeted therapies that have been approved in the United States, Canada, or Europe.
Keywords: targeted therapies; non-small-cell lung cancer; nsclc; metastatic; maintenance targeted therapies; non-small-cell lung cancer; nsclc; metastatic; maintenance
MDPI and ACS Style

Hirsh, V. Systemic Therapies in Metastatic Non-Small-Cell Lung Cancer with Emphasis on Targeted Therapies: The Rational Approach. Curr. Oncol. 2010, 17, 13-23. https://0-doi-org.brum.beds.ac.uk/10.3747/co.v17is1.615

AMA Style

Hirsh V. Systemic Therapies in Metastatic Non-Small-Cell Lung Cancer with Emphasis on Targeted Therapies: The Rational Approach. Current Oncology. 2010; 17(2):13-23. https://0-doi-org.brum.beds.ac.uk/10.3747/co.v17is1.615

Chicago/Turabian Style

Hirsh, Vera. 2010. "Systemic Therapies in Metastatic Non-Small-Cell Lung Cancer with Emphasis on Targeted Therapies: The Rational Approach" Current Oncology 17, no. 2: 13-23. https://0-doi-org.brum.beds.ac.uk/10.3747/co.v17is1.615

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop